ROCKVILLE, Md.--Celera Genomics’ stock price continued its climb on news of a planned two-for-one split, along with the announcement that it and the Berkeley, Calif., genomics firm Neomorphic have developed a browser software application for accessing Celera’s genomic databases.
The browser has been designed to enable Celera and its customers to research the human and Drosophila genomes for medically relevant and commercially valuable genes in the context of a complete genome. The price of Celera’s stock closed more than $10 up at $226.375 on the day of the announcements, according to SunSpot, the Baltimore Sun’s online news service.
Separately, Celera has also taken over a 47.5 percent equity stake in Shanghai GeneCore BioTechnologies, a genomics service company, from Axys Pharmaceuticals. The Chinese company said it is involved in nucleotide synthesis, DNA sequencing, bioinformatics analysis, and mutation detection and has ongoing research collaborations with several Chinese government agencies and research institutes.